Breaking Finance News

A statement released earlier today by Leerink Swann about Atricure Inc. (NDAQ:ATRC) bumps the target price to $26.00

Boasting a price of $21.84, Atricure Inc. (NDAQ:ATRC) traded 0.92% higher on the day. The last stock close price is up 2.58% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. ATRC has recorded a 50-day average of $21.90 and a 200-day moving average of $21.44. 113,139 shares of ATRC traded hands, down from an average trading volume of 184,802

Leerink Swann bumped up the target of Atricure Inc. (NDAQ:ATRC) to $26.00 stating a potential upside of 0.19%.

Recent Performance Chart

Atricure Inc. (NDAQ:ATRC)

Atricure Inc. has 52 week low of $14.78 and a 52 week high of $25.18 and has a market capitalization of $0.

In addition to Leerink Swann reporting its stock price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $24.00 with 4 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Atricure Inc. (NDAQ:ATRC)

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.